S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910